Immuron Limited Reports Unaudited Net Sales Results for the Year to Date Ended January 2024

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects in Australia, Israel and the United States. The Company's flagship commercial products consist of Travelan and Protectyn. Travelan is an over the counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers' diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. The Company has four clinical programs -Travelan (IMM-124E), CampETEC, IMM-529 and Travelan (consumer product).